This article was originally published in The Tan Sheet
The Council for Responsible Nutrition requests a 90-day extension period to comment on the status of pyridoxamine as a dietary supplement. "There is very strong evidence" that the ingredient was marketed prior to the enactment of DSHEA, CRN maintains in a Dec. 16 letter to FDA. However, the group began contacting members in November for evidence of sale and "the search for documentary evidence is proving difficult and tedious." CRN has identified two firms "whose former employees believe they marketed pyridoxamine during that era" and who are continuing their search for evidence. FDA sought comment in a Nov. 18 Federal Register that "tentatively" concluded the ingredient was not a supplement ("The Tan Sheet" Nov. 21, 2005, p. 13). Debate began when a July citizen petition by BioStratum requested that sales of supplements containing pyridoxamine cease. The firm filed an investigational new drug application in 1999 for Pyridorin, which contains the ingredient...
You may also be interested in...
FDA tentatively has concluded that pyridoxamine is not a dietary supplement and has opened a 30-day comment period inviting information on the ingredient's prior marketing as a dietary ingredient or food
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.